slide1 n.
Download
Skip this Video
Loading SlideShow in 5 Seconds..
Authors: Joensuu H et al. Reviewed By: Dr. Vincent Tam Abstract: ASCO 2011 Abstract 1 Date posted: June 2011 PowerPoint Presentation
Download Presentation
Authors: Joensuu H et al. Reviewed By: Dr. Vincent Tam Abstract: ASCO 2011 Abstract 1 Date posted: June 2011

Loading in 2 Seconds...

play fullscreen
1 / 8

Authors: Joensuu H et al. Reviewed By: Dr. Vincent Tam Abstract: ASCO 2011 Abstract 1 Date posted: June 2011 - PowerPoint PPT Presentation


  • 234 Views
  • Uploaded on

Twelve versus 36 months of adjuvant imatinib as treatment of operable GIST with a high risk of recurrence: Final results of a randomized trial (SSGXVIII/AIO). Authors: Joensuu H et al. Reviewed By: Dr. Vincent Tam Abstract: ASCO 2011 Abstract 1 Date posted: June 2011.

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'Authors: Joensuu H et al. Reviewed By: Dr. Vincent Tam Abstract: ASCO 2011 Abstract 1 Date posted: June 2011' - erzsebet


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
slide1

Twelve versus 36 months of adjuvant imatinib as treatment of operable GIST with a high risk of recurrence: Final results of a randomized trial (SSGXVIII/AIO)

Authors: Joensuu H et al.

Reviewed By: Dr. Vincent Tam

Abstract: ASCO 2011 Abstract 1

Date posted: June 2011

slide2

Thank you for downloading this update. Please feel free to use it for educational purposes.

Please acknowledge OncologyEducation.ca and Dr. Vincent Tam when using these slides.

slide3

Study Design

N= 400 (1:1 randomization)

Stratification:

1) R0 resection, no tumor rupture

2) R1 resection, tumor rupture

Primary Outcome: RFS

Treatment A:

IMATINIB 400mg daily x 12 months

R

Treatment B:

IMATINIB 400mg daily x 36 months

slide4

INCLUSION CRITERIA

  • Histologically confirmed GIST, KIT-positive
  • High risk of recurrence according to the Modified Consensus Criteria:
    • Tumor diameter > 10cm or
    • Tumor mitosis count >10/50 HPF or
    • Size >5cm and mitosis count >5/50 HPF or
    • Tumor rupture spontaneously or at surgery
slide5

RESULTS*

* Intention-to-treat analysis

slide7

STUDY COMMENTARY

  • Well designed adjuvant study which demonstrated a statistically significant increase in RFS and OS with 36 months of imatinib
  • Higher rate of discontinuing imatinib prior to complete course in 36 month arm due to adverse events, but also due to “other reasons” possibly related to patients not willing to take a drug for years without any evidence of disease
  • Is there additional benefit of continuing imabinib beyond 36 months, perhaps indefinitely?
slide8

BOTTOM LINE FOR CANADIAN MEDICAL ONCOLOGISTS

  • The standard of care for adjuvant treatment of GIST at high risk of recurrence is now 3 years of imatinib